Antibacterial activity of the natural product elaiophylin against Streptococcus suis and its biofilm eradication effect
- 1Hubei Biopesticide Engineering Research Centre, Wuhan, China
- 2College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, China
- 3Wuhan University of Science and Technology, Wuhan, China
Abstract
The multidrug resistance (MDR) problem in Streptococcus suis (S. suis) is becoming increasingly severe, necessitating the development of novel antibacterial agents and strategies. In this study, seven elaiophylin derivatives were isolated from Streptomyces sp. WS-30248, and the antibacterial activity and mechanism of action of the principal compound, elaiophylin, against S. suis were systematically evaluated for the first time. Through comprehensive approaches including in vitro efficacy assays, biofilm inhibition and eradication tests, bacterial membrane integrity analysis, reactive oxygen species (ROS) level detection, and a mouse infection model, elaiophylin was found to exhibit significant antibacterial activity against multiple clinically MDR S. suis strains. Its minimum inhibitory concentration (MIC) was as low as 0.5 μg/mL, and complete bactericidal activity was achieved within 24 h at 4× MIC. The compound effectively inhibited and eradicated bacterial biofilms, directly killing embedded cells within the biofilm matrix. Mechanistic studies revealed that elaiophylin functions through multiple synergistic pathways, including disruption of bacterial membrane integrity and induction of massive ROS accumulation, thereby interfering with the proton motive force (PMF), depleting intracellular ATP, and blocking energy metabolism. In the mouse infection model, the elaiophylin-treated group showed a significantly increased survival rate of 60% and effectively reduced bacterial loads in tissues. This study demonstrates that elaiophylin is a highly promising natural candidate drug with multi-target synergistic effects, offering a new strategy to combat MDR S. suis and biofilm-associated infections.
IMPORTANCE: This study is the first to systematically elucidate the potent antibacterial activity and multi-mechanism synergistic action of elaiophylin against multidrug-resistant (MDR) Streptococcus suis. It exerts its effects through multiple targeted pathways, including disrupting membrane integrity and inducing ROS accumulation and can effectively eradicate biofilms. It provides a highly promising novel candidate drug and a new strategy to combat the increasingly severe problem of MDR S. suis infections, holding significant theoretical and clinical value.
Related
- Study 9 — The Okinawa Natural Experiment: Strongyloides Eradication, HTLV-1 Suppression, and ATL Decline
- Editorial: Exploring natural extracts as sustainable antibacterial agents against aquaculture pathogens
- Targeting cariogenic virulence of Streptococcus mutans by pinosylvin: a promising anti-cariogenic natural agent
- Developmental Dynamics of Bioactive Composition and Biological Activities of Methanolic Extracts from Orange (Citrus sinensis) Peel: Comprehensive Metabolite Profiling, Antioxidant Capacity, and Antibacterial Activity
- The Production In Vivo of Microcin E492 with Antibacterial Activity Depends on Salmochelin and EntF
BibTeX
@article{liu2026antibacterial,
title = {{Antibacterial activity of the natural product elaiophylin against Streptococcus suis and its biofilm eradication effect}},
author = {Di Liu and Chang Chen and Qianqian Bao and Na Su and Yuhan Zhang and Xiliang Yang and Wei Fang and Chen Tan and Chenchen Wang and Manli Liu},
journal = {Microbiology Spectrum},
year = {2026},
month = oct,
doi = {10.1128/spectrum.03949-25},
url = {https://doi.org/10.1128/spectrum.03949-25},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Antibacterial activity of the natural product elaiophylin against Streptococcus suis and its biofilm eradication effect
AU - Di Liu
AU - Chang Chen
AU - Qianqian Bao
AU - Na Su
AU - Yuhan Zhang
AU - Xiliang Yang
AU - Wei Fang
AU - Chen Tan
AU - Chenchen Wang
AU - Manli Liu
PY - 2026
DA - 2026/10/08
JO - Microbiology Spectrum
DO - 10.1128/spectrum.03949-25
UR - https://doi.org/10.1128/spectrum.03949-25
AB - The multidrug resistance (MDR) problem in Streptococcus suis (S. suis) is becoming increasingly severe, necessitating the development of novel antibacterial agents and strategies. In this study, seven elaiophylin derivatives were isolated from Streptomyces sp. WS-30248, and the antibacterial activity and mechanism of action of the principal compound, elaiophylin, against S. suis were systematically evaluated for the first time. Through comprehensive approaches including in vitro efficacy assays, biofilm inhibition and eradication tests, bacterial membrane integrity analysis, reactive oxygen species (ROS) level detection, and a mouse infection model, elaiophylin was found to exhibit significant antibacterial activity against multiple clinically MDR S. suis strains. Its minimum inhibitory concentration (MIC) was as low as 0.5 μg/mL, and complete bactericidal activity was achieved within 24 h at 4× MIC. The compound effectively inhibited and eradicated bacterial biofilms, directly killing embedded cells within the biofilm matrix. Mechanistic studies revealed that elaiophylin functions through multiple synergistic pathways, including disruption of bacterial membrane integrity and induction of massive ROS accumulation, thereby interfering with the proton motive force (PMF), depleting intracellular ATP, and blocking energy metabolism. In the mouse infection model, the elaiophylin-treated group showed a significantly increased survival rate of 60% and effectively reduced bacterial loads in tissues. This study demonstrates that elaiophylin is a highly promising natural candidate drug with multi-target synergistic effects, offering a new strategy to combat MDR S. suis and biofilm-associated infections. IMPORTANCE: This study is the first to systematically elucidate the potent antibacterial activity and multi-mechanism synergistic action of elaiophylin against multidrug-resistant (MDR) Streptococcus suis. It exerts its effects through multiple targeted pathways, including disrupting membrane integrity and inducing ROS accumulation and can effectively eradicate biofilms. It provides a highly promising novel candidate drug and a new strategy to combat the increasingly severe problem of MDR S. suis infections, holding significant theoretical and clinical value.
SN - 2165-0497
ER -